Symbols / MLYS Stock $23.76 -1.74% Mineralys Therapeutics, Inc.
MLYS (Stock) Chart
Stock Fundamentals
|
|
|
|
|
|
About
Official websiteMineralys Therapeutics, Inc., a biopharmaceutical company, develops medicines to target diseases driven by dysregulated aldosterone in the United States. It is developing lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by dysregulated aldosterone, such as hypertension, chronic kidney disease, and obstructive sleep apnea. The company was formerly known as Catalys SC1, Inc. and changed its name to Mineralys Therapeutics, Inc. in May 2020. Mineralys Therapeutics, Inc. was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.
Ratings
Current target
$23.76
Low
$30.00
High
$56.00
Mean
$49.00
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-04-27 | init | TD Cowen | — → Buy | — |
| 2026-03-13 | main | B of A Securities | Buy → Buy | $51 |
| 2025-12-19 | main | Stifel | Buy → Buy | $52 |
| 2025-11-12 | main | HC Wainwright & Co. | Buy → Buy | $56 |
| 2025-11-11 | main | Wells Fargo | Overweight → Overweight | $55 |
| 2025-10-30 | main | HC Wainwright & Co. | Buy → Buy | $52 |
| 2025-09-11 | main | Wells Fargo | Overweight → Overweight | $50 |
| 2025-09-09 | main | Goldman Sachs | Buy → Buy | $52 |
| 2025-09-08 | reit | HC Wainwright & Co. | Buy → Buy | $42 |
| 2025-09-03 | main | Jefferies | Hold → Hold | $26 |
| 2025-08-28 | main | B of A Securities | Buy → Buy | $43 |
| 2025-08-13 | reit | HC Wainwright & Co. | Buy → Buy | $42 |
| 2025-06-17 | reit | HC Wainwright & Co. | Buy → Buy | $42 |
| 2025-06-11 | init | Jefferies | — → Hold | $15 |
| 2025-05-13 | reit | HC Wainwright & Co. | Buy → Buy | $42 |
| 2025-04-02 | main | HC Wainwright & Co. | Buy → Buy | $42 |
| 2025-03-10 | reit | HC Wainwright & Co. | Buy → Buy | $30 |
| 2025-02-24 | reit | Guggenheim | Buy → Buy | — |
| 2025-02-13 | main | Goldman Sachs | Buy → Buy | $24 |
| 2025-02-13 | reit | HC Wainwright & Co. | Buy → Buy | $30 |
- [144] Mineralys Therapeutics, Inc. SEC Filing - Stock Titan Wed, 10 Jun 2026 20
- Mineralys Therapeutics (MLYS) Shares Encouraging Data for Lorundrostat Clinical Efficacy - Yahoo Finance Fri, 05 Jun 2026 15
- Mineralys Therapeutics Stock In Shambles: Down -25% With 6-Day Losing Streak - Trefis Sat, 06 Jun 2026 05
- Velan Capital Drops 140,000 Mineralys Therapeutics (MLYS) Shares Worth $4.1 Million - AOL.com ue, 09 Jun 2026 14
- $MLYS stock is down 13% today. Here's what we see in our data. - Quiver Quantitative Wed, 03 Jun 2026 14
- 5 Best AI Driven Biotech Stocks to Invest In - Insider Monkey Wed, 10 Jun 2026 13
- Biopharma Mineralys joins Goldman Sachs health-care talks in Miami - Stock Titan Mon, 08 Jun 2026 20
- MLYS Stock Sees 17.1% Decline Amid Market Movements - GuruFocus hu, 04 Jun 2026 04
- Precision Trading with Mineralys Therapeutics Inc. (MLYS) Risk Zones - Stock Traders Daily Fri, 05 Jun 2026 16
- Congleton, Mineralys Therapeutics CEO, sells $421k in MLYS stock - Investing.com Wed, 15 Apr 2026 07
- Mineralys Therapeutics Stock Plummets 25% With 6-Day Losing Streak - Trefis Sat, 06 Jun 2026 04
- Is Mineralys Therapeutics, Inc. (MLYS) A Good Stock To Buy Now? - Yahoo Finance Sun, 03 May 2026 07
- Mineralys Therapeutics Prices Underwritten Offering of 5.6 Million Shares at $26.50 Per Share, Expected to Raise $150 Million - Quiver Quantitative Wed, 03 Jun 2026 10
- Biotech Mineralys raises $150M to help fund $200M royalty deal - Stock Titan Wed, 03 Jun 2026 10
- Is It Time To Reassess Mineralys Therapeutics (MLYS) After The Recent Share Price Pullback? - Yahoo Finance Fri, 20 Mar 2026 07
Insider Transactions
Financials
Statement View
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Revenue |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Operating Revenue |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Operating Expense |
|
170.60
-11.33%
|
192.40
+127.27%
|
84.66
+168.93%
|
31.48
|
| Research And Development |
|
132.01
-21.69%
|
168.58
+139.59%
|
70.36
+168.04%
|
26.25
|
| Selling General And Administration |
|
38.59
+62.01%
|
23.82
+66.63%
|
14.30
+173.40%
|
5.23
|
| General And Administrative Expense |
|
38.59
+62.01%
|
23.82
+66.63%
|
14.30
+173.40%
|
5.23
|
| Other Gand A |
|
38.59
+62.01%
|
23.82
+66.63%
|
14.30
+173.40%
|
5.23
|
| Total Expenses |
|
170.60
-11.33%
|
192.40
+127.27%
|
84.66
+168.93%
|
31.48
|
| Operating Income |
|
-170.60
+11.33%
|
-192.40
-127.27%
|
-84.66
-168.93%
|
-31.48
|
| Total Operating Income As Reported |
|
-170.60
+11.33%
|
-192.40
-127.27%
|
-84.66
-168.93%
|
-31.48
|
| EBITDA |
|
-170.54
+11.34%
|
-192.36
-127.22%
|
-84.66
-168.93%
|
-31.48
|
| Normalized EBITDA |
|
-170.54
+11.34%
|
-192.36
-127.22%
|
-84.66
-168.93%
|
-31.48
|
| Reconciled Depreciation |
|
0.06
+37.21%
|
0.04
|
0.00
|
—
|
| EBIT |
|
-170.60
+11.33%
|
-192.40
-127.27%
|
-84.66
-168.93%
|
-31.48
|
| Total Unusual Items |
|
—
|
—
|
—
|
—
|
| Total Unusual Items Excluding Goodwill |
|
—
|
—
|
—
|
—
|
| Net Income |
|
-154.65
+13.02%
|
-177.81
-147.31%
|
-71.90
-141.28%
|
-29.80
|
| Pretax Income |
|
-154.65
+13.02%
|
-177.81
-147.31%
|
-71.90
-141.28%
|
-29.80
|
| Net Non Operating Interest Income Expense |
|
15.95
+9.36%
|
14.59
+14.36%
|
12.76
+661.10%
|
1.68
|
| Interest Expense Non Operating |
|
—
|
—
|
—
|
—
|
| Net Interest Income |
|
15.95
+9.36%
|
14.59
+14.36%
|
12.76
+661.10%
|
1.68
|
| Interest Expense |
|
—
|
—
|
—
|
—
|
| Interest Income Non Operating |
|
15.95
+9.36%
|
14.59
+14.36%
|
12.76
+661.10%
|
1.68
|
| Interest Income |
|
15.95
+9.36%
|
14.59
+14.36%
|
12.76
+661.10%
|
1.68
|
| Other Income Expense |
|
—
|
0.01
+66.67%
|
0.00
-25.00%
|
0.00
|
| Other Non Operating Income Expenses |
|
—
|
0.01
+66.67%
|
0.00
-25.00%
|
0.00
|
| Gain On Sale Of Security |
|
—
|
—
|
—
|
—
|
| Tax Rate For Calcs |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Tax Effect Of Unusual Items |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Net Income Including Noncontrolling Interests |
|
-154.65
+13.02%
|
-177.81
-147.31%
|
-71.90
-141.28%
|
-29.80
|
| Net Income From Continuing Operation Net Minority Interest |
|
-154.65
+13.02%
|
-177.81
-147.31%
|
-71.90
-141.28%
|
-29.80
|
| Net Income From Continuing And Discontinued Operation |
|
-154.65
+13.02%
|
-177.81
-147.31%
|
-71.90
-141.28%
|
-29.80
|
| Net Income Continuous Operations |
|
-154.65
+13.02%
|
-177.81
-147.31%
|
-71.90
-141.28%
|
-29.80
|
| Normalized Income |
|
-154.65
+13.02%
|
-177.81
-147.31%
|
-71.90
-141.28%
|
-29.80
|
| Net Income Common Stockholders |
|
-154.65
+13.02%
|
-177.81
-147.31%
|
-71.90
-141.28%
|
-29.80
|
| Otherunder Preferred Stock Dividend |
|
—
|
—
|
—
|
—
|
| Diluted EPS |
|
-2.29
+37.43%
|
-3.66
-83.92%
|
-1.99
-160.82%
|
-0.76
|
| Basic EPS |
|
-2.29
+37.43%
|
-3.66
-83.92%
|
-1.99
-160.82%
|
-0.76
|
| Basic Average Shares |
|
67.66
+39.38%
|
48.54
+34.13%
|
36.19
-7.34%
|
39.06
|
| Diluted Average Shares |
|
67.66
+39.38%
|
48.54
+34.13%
|
36.19
-7.34%
|
39.06
|
| Diluted NI Availto Com Stockholders |
|
-154.65
+13.02%
|
-177.81
-147.31%
|
-71.90
-141.28%
|
-29.80
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Assets |
|
661.81
+221.42%
|
205.90
-18.17%
|
251.64
+119.88%
|
114.44
|
| Current Assets |
|
661.39
+222.08%
|
205.35
-17.56%
|
249.10
+120.81%
|
112.81
|
| Cash Cash Equivalents And Short Term Investments |
|
656.63
+231.32%
|
198.19
-16.22%
|
236.57
+114.85%
|
110.11
|
| Cash And Cash Equivalents |
|
172.92
+51.56%
|
114.09
+131.40%
|
49.30
-43.78%
|
87.70
|
| Cash Equivalents |
|
171.89
+51.54%
|
113.43
+133.10%
|
48.66
-42.64%
|
84.83
|
| Cash Financial |
|
1.03
+55.12%
|
0.66
+3.27%
|
0.64
-77.61%
|
2.87
|
| Other Short Term Investments |
|
483.71
+475.19%
|
84.10
-55.09%
|
187.26
+735.66%
|
22.41
|
| Prepaid Assets |
|
—
|
—
|
—
|
—
|
| Other Current Assets |
|
4.75
-33.68%
|
7.16
-42.85%
|
12.54
+364.12%
|
2.70
|
| Total Non Current Assets |
|
0.42
-23.91%
|
0.55
-78.21%
|
2.53
+55.30%
|
1.63
|
| Net PPE |
|
0.04
-28.30%
|
0.05
|
0.00
|
—
|
| Investments And Advances |
|
—
|
0.00
-100.00%
|
2.48
|
0.00
|
| Other Investments |
|
—
|
0.00
-100.00%
|
2.48
|
0.00
|
| Non Current Deferred Assets |
|
—
|
—
|
0.05
-96.87%
|
1.63
|
| Other Non Current Assets |
|
0.38
-23.45%
|
0.50
+878.43%
|
0.05
|
—
|
| Total Liabilities Net Minority Interest |
|
15.11
+3.19%
|
14.65
+39.73%
|
10.48
-93.71%
|
166.71
|
| Current Liabilities |
|
15.11
+3.19%
|
14.65
+39.73%
|
10.48
+29.94%
|
8.07
|
| Payables And Accrued Expenses |
|
9.57
-13.48%
|
11.06
+24.55%
|
8.88
+20.01%
|
7.40
|
| Payables |
|
2.02
+321.09%
|
0.48
-20.30%
|
0.60
-68.48%
|
1.91
|
| Accounts Payable |
|
2.02
+321.09%
|
0.48
-20.30%
|
0.60
-68.48%
|
1.91
|
| Current Accrued Expenses |
|
7.56
-28.62%
|
10.59
+27.81%
|
8.28
+50.72%
|
5.50
|
| Pensionand Other Post Retirement Benefit Plans Current |
|
5.54
+54.66%
|
3.58
+124.02%
|
1.60
+140.45%
|
0.67
|
| Total Non Current Liabilities Net Minority Interest |
|
0.00
|
0.00
|
0.00
-100.00%
|
158.64
|
| Preferred Securities Outside Stock Equity |
|
—
|
0.00
|
0.00
-100.00%
|
158.64
|
| Stockholders Equity |
|
646.69
+238.13%
|
191.26
-20.69%
|
241.15
+561.37%
|
-52.27
|
| Common Stock Equity |
|
646.69
+238.13%
|
191.26
-20.69%
|
241.15
+561.37%
|
-52.27
|
| Capital Stock |
|
0.01
+60.00%
|
0.01
+25.00%
|
0.00
+300.00%
|
0.00
|
| Common Stock |
|
0.01
+60.00%
|
0.01
+25.00%
|
0.00
+300.00%
|
0.00
|
| Preferred Stock |
|
—
|
—
|
—
|
—
|
| Share Issued |
|
81.54
+63.66%
|
49.82
+21.12%
|
41.13
+5.32%
|
39.06
|
| Ordinary Shares Number |
|
81.54
+63.66%
|
49.82
+21.12%
|
41.13
+5.32%
|
39.06
|
| Additional Paid In Capital |
|
1,103.85
+123.56%
|
493.77
+34.96%
|
365.86
+67651.48%
|
0.54
|
| Retained Earnings |
|
-457.17
-51.12%
|
-302.52
-142.58%
|
-124.71
-136.14%
|
-52.81
|
| Total Equity Gross Minority Interest |
|
646.69
+238.13%
|
191.26
-20.69%
|
241.15
+561.37%
|
-52.27
|
| Total Capitalization |
|
646.69
+238.13%
|
191.26
-20.69%
|
241.15
+561.37%
|
-52.27
|
| Working Capital |
|
646.27
+238.89%
|
190.71
-20.08%
|
238.62
+127.81%
|
104.74
|
| Invested Capital |
|
646.69
+238.13%
|
191.26
-20.69%
|
241.15
+561.37%
|
-52.27
|
| Net Tangible Assets |
|
646.69
+238.13%
|
191.26
-20.69%
|
241.15
+561.37%
|
-52.27
|
| Tangible Book Value |
|
646.69
+238.13%
|
191.26
-20.69%
|
241.15
+561.37%
|
-52.27
|
| Preferred Stock Equity |
|
—
|
—
|
—
|
—
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Operating Cash Flow |
|
-142.42
+14.37%
|
-166.31
-104.89%
|
-81.17
-177.79%
|
-29.22
|
| Cash Flow From Continuing Operating Activities |
|
-142.42
+14.37%
|
-166.31
-104.89%
|
-81.17
-177.79%
|
-29.22
|
| Net Income From Continuing Operations |
|
-154.65
+13.02%
|
-177.81
-147.31%
|
-71.90
-141.28%
|
-29.80
|
| Depreciation Amortization Depletion |
|
0.06
+37.21%
|
0.04
|
0.00
|
—
|
| Depreciation And Amortization |
|
0.06
+37.21%
|
0.04
|
0.00
|
—
|
| Other Non Cash Items |
|
-9.88
-5.04%
|
-9.40
-37.00%
|
-6.87
-957.78%
|
-0.65
|
| Stock Based Compensation |
|
19.32
+70.47%
|
11.34
+124.03%
|
5.06
+1012.09%
|
0.46
|
| Unrealized Gain Loss On Investment Securities |
|
—
|
—
|
—
|
—
|
| Change In Working Capital |
|
2.73
-71.32%
|
9.52
+227.47%
|
-7.47
-1067.62%
|
0.77
|
| Change In Receivables |
|
-0.17
-139.15%
|
0.42
+219.44%
|
-0.35
|
0.00
|
| Change In Prepaid Assets |
|
2.47
-49.95%
|
4.93
+151.78%
|
-9.53
-325.45%
|
-2.24
|
| Change In Payables And Accrued Expense |
|
0.43
-89.74%
|
4.16
+72.38%
|
2.42
-19.82%
|
3.01
|
| Investing Cash Flow |
|
-389.75
-439.04%
|
114.96
+171.64%
|
-160.47
-637.50%
|
-21.76
|
| Cash Flow From Continuing Investing Activities |
|
-389.75
-439.04%
|
114.96
+171.64%
|
-160.47
-637.50%
|
-21.76
|
| Net PPE Purchase And Sale |
|
-0.01
+84.38%
|
-0.10
|
0.00
|
—
|
| Purchase Of PPE |
|
-0.01
+84.38%
|
-0.10
|
0.00
|
—
|
| Capital Expenditure |
|
-0.01
+84.38%
|
-0.10
|
—
|
—
|
| Net Investment Purchase And Sale |
|
-389.74
-438.74%
|
115.06
+171.70%
|
-160.47
-637.50%
|
-21.76
|
| Purchase Of Investment |
|
-814.74
-118.17%
|
-373.44
-7.32%
|
-347.97
-384.92%
|
-71.76
|
| Sale Of Investment |
|
425.00
-13.00%
|
488.50
+160.53%
|
187.50
+275.00%
|
50.00
|
| Financing Cash Flow |
|
591.00
+408.86%
|
116.14
-42.86%
|
203.25
+58.76%
|
128.02
|
| Cash Flow From Continuing Financing Activities |
|
591.00
+408.86%
|
116.14
-42.86%
|
203.25
+58.76%
|
128.02
|
| Net Issuance Payments Of Debt |
|
—
|
—
|
—
|
—
|
| Issuance Of Debt |
|
—
|
—
|
—
|
—
|
| Short Term Debt Issuance |
|
—
|
—
|
—
|
—
|
| Net Short Term Debt Issuance |
|
—
|
—
|
—
|
—
|
| Net Common Stock Issuance |
|
578.36
+398.33%
|
116.06
-42.83%
|
202.99
+12561.02%
|
-1.63
|
| Common Stock Payments |
|
—
|
—
|
—
|
-1.63
|
| Repurchase Of Capital Stock |
|
—
|
—
|
—
|
-1.63
|
| Proceeds From Stock Option Exercised |
|
13.03
+2415.25%
|
0.52
+100.78%
|
0.26
|
0.00
|
| Net Other Financing Charges |
|
-0.39
+10.11%
|
-0.43
|
—
|
-1.63
|
| Changes In Cash |
|
58.83
-9.19%
|
64.79
+268.73%
|
-38.40
-149.84%
|
77.04
|
| Beginning Cash Position |
|
114.09
+131.40%
|
49.30
-43.78%
|
87.70
+722.56%
|
10.66
|
| End Cash Position |
|
172.92
+51.56%
|
114.09
+131.40%
|
49.30
-43.78%
|
87.70
|
| Free Cash Flow |
|
-142.43
+14.41%
|
-166.41
-105.01%
|
-81.17
-177.79%
|
-29.22
|
| Common Stock Issuance |
|
578.36
+398.33%
|
116.06
-42.83%
|
202.99
|
—
|
| Issuance Of Capital Stock |
|
578.36
+398.33%
|
116.06
-42.83%
|
202.99
+56.57%
|
129.65
|
| Net Preferred Stock Issuance |
|
—
|
—
|
0.00
-100.00%
|
129.65
|
| Preferred Stock Issuance |
|
—
|
—
|
0.00
-100.00%
|
129.65
|
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
- 8-K2026-06-03 View
- 8-K2026-06-03 View
- 8-K2026-05-22 View
- 42026-05-19 View
- 42026-05-13 View
- 10-Q2026-05-06 View
- 8-K2026-05-06 View
- 42026-04-21 View
- 42026-04-15 View
- 42026-04-15 View
- 42026-04-13 View
- 42026-04-02 View
- 42026-04-02 View
- 42026-03-31 View
- 42026-03-17 View
- 42026-03-16 View
- 10-K2026-03-12 View
- 8-K2026-03-12 View
- 42026-03-10 View
- 8-K2026-03-09 View
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|